Funding shortfall
The company states it will need additional capital to fund R&D and obligations.
- Scope
- Could delay, scale back, or discontinue development programs
- Materiality
- high
Rocket One Inc.
Rocket One Inc. is a U.S.-based pharmaceutical preparations company focused on pre-clinical and clinical development of product candidates. The company operates as a development-stage biopharmaceutical business and has not yet commercialized any products.
4.72
| % | |
|---|---|
| Pre-clinical and clinical development | 100% Research, testing, and advancement of drug candidates through pre-clinical and clinical stages. |
| Licensing and collaboration agreements | 0% License, sublicense, sponsored research, and option agreements tied to pipeline development. |
Rocket One's direct counterparties are primarily licensing partners, research collaborators, and other third parties...
- Licensing and collaboration partnersprimary
Third parties that enter license, sublicense, sponsored research, and option agreements to access pipeline assets or share development economics.
- Capital providersprimary
Equity and debt investors that fund ongoing R&D and working capital needs while the company remains pre-revenue.
- Future healthcare end usersemerging
Patients, physicians, and healthcare systems that would use approved products if development succeeds.
Rocket One is headquartered in the United States and its reported disclosures are U.S.-centric...
- •Headquartered in the United States
- •Primary regulatory and capital-market exposure is U.S.-based
- •Development-stage operations are centered on U.S. filings and financing
- •No product revenue geography disclosed
- •No authoritative regional revenue breakdown provided
The company’s strategy is centered on advancing pre-clinical and clinical product candidates while securing the capital...
01
Raise additional capitalshort-term
Development-stage biopharma requires external funding before product revenue exists.
02
Advance pipeline assetsmedium-term
Clinical and pre-clinical progress is the main driver of future value creation.
03
Commercialize future productslong-term
Long-term value depends on moving from development to approved, marketable therapies.
Rocket One faces the classic risks of a development-stage biopharmaceutical company: it may never successfully advance...
Clinical and development failure
Pre-clinical and clinical assets may not achieve required safety or efficacy outcomes.
- Scope
- Pipeline value and future commercialization prospects
- Materiality
- high
Digital asset custody and cyber risk
The company disclosed that digital assets are held at Coinbase and are exposed to breaches.
- Scope
- Potential loss of digital assets and reputational harm
- Materiality
- medium
Partner and milestone obligations
License and research agreements may require maintenance fees, royalties, and milestones.
- Scope
- Cash outflows and contractual dependence on third parties
- Materiality
- medium
Healthcare reimbursement and regulatory pressure
Drug commercialization depends on approval, pricing, and reimbursement conditions.
- Scope
- Future market access and revenue realization
- Materiality
- high
Stock-based compensation
Can materially change general and administrative and R&D expense
Going-concern assessment
Affects financial statement presentation and investor assessment of solvency
Contingent license obligations
Potential future liabilities and cash outflows
Digital asset custody and valuation
Can affect balance sheet presentation and risk disclosures
: 16/06/2026